Results 211 to 220 of about 170,034 (262)

Benzimidazole scaffold as a potent anticancer agent with different mechanisms of action (2016-2023). [PDF]

Mol Divers
Hagar FF, Abbas SH, Atef E, Abdelhamid D, Abdel-Aziz M.   +4 more
europepmc   +1 more source

PANX2 Suppresses Lung Adenocarcinoma Progression by Inducing Disulfidptosis and Enhancing Antitumor Immunity

Advanced Science, EarlyView.
ABSTRACT Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality with limited therapeutic options. Disulfidptosis, a novel cell death modality driven by disulfide stress, represents a promising target, yet its regulation in LUAD is poorly defined. Here, we identify Pannexin 2 (PANX2) as a tumor suppressor in LUAD.
Yi Chen, Zhao‐Yu Liu, Gao‐Wen Qu, Run‐Hao Zeng, Wen‐Xia Yao, Yong‐Bing Zhou, Xue Liang, Yu‐Xiong Lai   +7 more
wiley   +1 more source

Article review: Brazilin as potential anticancer agent. [PDF]

Front Pharmacol
Raptania CN, Zakia S, Fahira AI, Amalia R.   +3 more
europepmc   +1 more source

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

Advanced Science, EarlyView.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng, Chao He, Zhibin He, Hongbo Chen, Fang Cheng, Yongjiang Zheng   +5 more
wiley   +1 more source

A novel gemcitabine analog as a potential anticancer agent: synthesis and <i>in-vitro</i> evaluation against pancreatic cancer. [PDF]

Am J Cancer Res
Okoro J, Bulusu R, Frimpong E, Zhu X, Rogers S, Agyare E.   +5 more
europepmc   +1 more source

Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

Advanced Science, EarlyView.
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia, Hui You, Ke Zhang, Hui Jiang, Hongping Liu, Lianghua Liu, Aijie Zhang, You Zhou   +7 more
wiley   +1 more source

Updated aspects of alpha-Solanine as a potential anticancer agent: Mechanistic insights and future directions. [PDF]

Food Sci Nutr
Nandi S, Sikder R, Nag A, Khatua S, Sen S, Chakraborty N, Naskar A, Zhakipbekov K, Acharya K, Habtemariam S, Arslan Ateşşahin D, Goloshvili T, Ahmed Aldahish A, Sharifi-Rad J, Calina D.   +14 more
europepmc   +1 more source

Supramolecular Assembly of Stepped‐Persistent ROS Nanogenerator for Sustained Tumor Immunotherapy

Advanced Science, EarlyView.
ROS catalytic systems often fail to achieve both effective tumor elimination and persistent immune activation due to their monotonous ROS production profiles. A stepped‐persistent ROS nanogenerator was developed by supramolecularly assembling multiple ROS generation modules within a nanofiber structure to simultaneously extend ROS generation duration ...
Zhenqiang Wang, Ming Qin, Wenjing Lai, Shiwen Chen, Fengling Wang, Dandan Xie, Maohua Chen, Changpeng Hu, Kui Wang, Rong Zhang, Guobing Li   +10 more
wiley   +1 more source

Piperazine-Based Co(III), Ni(II), Cu(II), and Zn(II) Carbodithioate Complexes as Potential Anticancer Agent. [PDF]

ACS Omega
Gupta S, Shukla A, Pandey SK, Jha S, Zewde B, Acharya A, Butcher RJ, Bharty MK.   +7 more
europepmc   +1 more source

Targeting PLD3 Reverses the Immunosuppressive Niche by Reprogramming Tumor‐Associated Macrophages and Potentiates Antitumor Immunity

Advanced Science, EarlyView.
PLD3 activates the lysosomal‐AKT‐NF‐κB axis to drive cellular senescence in macrophages, establishing an immunosuppressive TME by limiting the infiltration of cytotoxic T, NK, and NKT cells, which confers resistance to anti‐PD‐1 therapy. Abrine inhibits PLD3 expression, restoring antitumor immunity and synergizing with anti‐PD‐1 treatment.
Xingtu Qin, Qiong Li, Xuemei Xu, Yuhan Wu, Yin Zhu, Jieqiong Wu, Yuan Fang, Qiubei Chen, Shuyang Wang, Jiang Yu, Yaping Ye, Hongli Jiao   +11 more
wiley   +1 more source